{
    "patientData": {
        "name": "Sarah Miller",
        "mrn": "MC-001001",
        "age_sex": "63-year-old Female",
        "date_of_summary": "2025-10-14",
        "one_sentence_impression": "Sarah Miller, a 63-year-old female with rheumatoid arthritis, developed acute liver injury and hepatic encephalopathy following initiation of Trimethoprim-Sulfamethoxazole, likely due to a drug-induced liver injury (DILI) exacerbated by chronic Methotrexate use.",
        "clinical_context_baseline": {
            "comorbidities": [
                "Rheumatoid arthritis",
                "Essential hypertension",
                "Mild chronic kidney disease"
            ],
            "key_baseline_labs": "Baseline labs prior to 2025-06-15 showed stable renal function (eGFR ~58-85 mL/min/1.73m2) and normal liver enzymes (ALT/AST <40 U/L, Total Bilirubin <1.2 mg/dL).",
            "social_history": "Drinks 1-2 beers/day (7-14 units/week); quit smoking in 2017 (20 pack-year history)."
        },
        "suspect_drug_timeline": {
            "chief_complaint": "Severe fatigue, jaundice, epigastric pain, confusion.",
            "hopi_significant_points": "Patient started Trimethoprim-Sulfamethoxazole (TMP-SMX) on 2025-06-15 for sinusitis. By 2025-06-20, she developed fatigue, mouth ulcers, nausea, and jaundice. Presented to ED on 2025-06-21 with severe fatigue, jaundice, epigastric pain, and confusion.",
            "chronic_medications": [
                "Methotrexate 20 mg weekly (started 2018-09-05, previously 10mg weekly from 2015-08-10)",
                "Folic Acid 5 mg weekly (started 2015-08-10)",
                "Lisinopril 10 mg daily (started 2018-09-05)"
            ],
            "acute_medication_onset": "Trimethoprim-Sulfamethoxazole 800/160 mg BID started on 2025-06-15.",
            "possibilities_for_dili": [
                "Trimethoprim-Sulfamethoxazole",
                "Methotrexate"
            ]
        },
        "rule_out_complete": {
            "viral_hepatitis": "Pending",
            "autoimmune": "Pending",
            "other_competing_dx_ruled_out": "No fever or hemodynamic instability to suggest ischemic or septic hepatitis. No known autoimmune or metabolic history."
        },
        "injury_pattern_trends": {
            "pattern": "Hepatocellular",
            "hys_law": "Present. Elevated ALT/AST (>20x ULN) with elevated bilirubin (>3x ULN) and elevated INR suggest severe liver injury with potential for Hy's Law.",
            "meld_na": "Not calculable due to missing values for sodium and bilirubin on admission labs.",
            "lft_data_peak_onset": {
                "ALT": "2100 U/L",
                "AST": "1650 U/L",
                "Alk_Phos": "350 U/L",
                "T_Bili": "12.5 mg/dL",
                "INR": "1"
            },
            "lft_sparklines_trends": "Baseline LFTs were normal. Elevated to ALT 40 U/L and AST 35 U/L on 2025-06-15. On 2025-06-21, ALT rose to 1650 U/L and AST to 2100 U/L with elevated bilirubin and INR.",
            "complications": [
                "Hepatic Encephalopathy (GCS 13, asterixis, disorientation)",
                "Pancytopenia (implied by low WBC/Platelets in ED dictation, specific lab values pending)",
                "Oral mucosal ulcerations"
            ],
            "noh_graz_law": "Not applicable, as paracetamol toxicity is not suspected."
        },
        "severity_prognosis": {
            "severity_features": [
                "Acute liver failure",
                "Hepatic Encephalopathy",
                "Elevated INR",
                "Markedly elevated ALT/AST and Bilirubin"
            ],
            "prognosis_statement": "The patient presents with severe acute liver injury, meeting criteria for acute liver failure, with significant risk for mortality or need for liver transplantation if recovery does not occur. Prognosis is guarded and requires intensive monitoring and supportive care."
        },
        "key_diagnostics": {
            "imaging_performed": "STAT abdominal ultrasound ordered (results not specified).",
            "biopsy": "Not performed at presentation.",
            "methotrexate_level": "STAT Methotrexate level ordered."
        },
        "management_monitoring": {
            "stopped_culprit_drugs": [
                "Methotrexate",
                "Trimethoprim-Sulfamethoxazole"
            ],
            "active_treatments": [
                "IV fluids",
                "N-acetylcysteine protocol"
            ],
            "consults_initiated": [
                "Gastroenterology/Hepatology",
                "Hematology",
                "Intensive Care Unit (ICU)"
            ],
            "nutrition": "NPO (Nil Per Os).",
            "vte_ppx": "Not specified.",
            "causality_rucam": "RUCAM score is 7, categorizing the causality as 'Probable' for TMP-SMX, with Methotrexate as a significant co-factor.",
            "monitoring_plan": [
                "Frequent neurological checks",
                "Continued laboratory monitoring (CBC, CMP, Coags, MTX level, Ammonia, Hepatitis panel, Autoimmune panel)",
                "Monitoring for complications (e.g., bleeding, infection, hemodynamic instability)"
            ]
        },
        "current_status_last_48h": "Patient presented to the Emergency Department on 2025-06-21 with acute onset of severe fatigue, jaundice, epigastric pain, and confusion, indicating a rapid clinical deterioration over the preceding 24-48 hours, directly following initiation of TMP-SMX."
    }
}